RxDoctor Payments Data

William Oconnor, MD

Neurology · Media, PANPI 1730132507

Payments from drug & device makers

$4,125in general payments, 2019–2025

Across 293 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$881
  • AbbVie$690
  • Pfizer$567
  • Biogen$422
  • SK Life Science, Inc.$353
  • Novartis$333
  • plus $880 from 18 others

What the payments were for

  • Food & beverage$3,79792%
  • Education$3288%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,125 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$229,719
Medicare patients
655
Services billed
2,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$259,154
Nurtec OdtRimegepant Sulfate18$33,479
Memantine Hcl ErMemantine Hcl93$9,444
Rasagiline Mesylate25$9,020
Rufinamide13$7,354
Levetiracetam135$7,241
Oxcarbazepine40$4,461
Carbamazepine27$2,772
Memantine Hcl119$2,724
Carbamazepine ErCarbamazepine13$2,240
Phenytoin Sodium Extended52$1,800
Zonisamide53$1,693
Lacosamide25$1,689
Rivastigmine11$1,581
Pregabalin55$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$567$33,47918 claims
Upsher-smith Laboratories LLCTopiramate$25$1,06631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →